| Vatican Endorsement Seals Neostem's Status as Leading Stem Cell Play M.E. Garza submits: Just as we have speculated in articles and trade alerts for the past few weeks, the Roman Catholic church appears to be getting ready to support Neostem's (AMEX:NBS) stem cell initiatives in a very big way and one can only imagine the types of new headlines this news may generate both on and off Wall Street. One of the biggest questions now is just how high NBS shares will run on news of the scientific support that would have made Galileo jealous. An easy double? Perhaps easily over $10 or $15, given the fact that the company should be easily trading at $6 per share now without the news? Analysts I spoke to Wednesday morning say it's too soon to tell since historic news like this isn't announced very often.NBS announced Wednesday morning that the Vatican’s Pontifical Council for Culture announced a joint 5 year initiative between the companies and their charitable organizations to expand research and raise awareness of adult stem cell therapies. NeoStem’s Stem for Life Foundation, formed to create awareness about the promise of adult stem cells to treat disease, and the Pontifical Council’s Foundation, called STOQ International (Science Theology and the Ontological Quest), will work on a variety of collaborative activities with the goal of advancing scientific research on adult stem cells, exploring their clinical application in the field of regenerative medicine and the cultural relevance of such a fundamental shift in medical treatment options, particularly with regard to the impact on theological and ethical issues. As we understand it, this Vatican has endorsed NBS's method of extraction and storage of autologus (self-derived) adult stem cells as well as the growing number of NBS's proprietary treatments for these cells in the orthopedic, cardiovascular, and cosmetic areas.Complete Story » seekingalpha.com |
Boston Scientific Issues Advisory on Defibrillators Boston Scientific had sent an advisory to physicians on some models of its implantable heart defibrillators. online.wsj.com |
King Pharma's Profit Falls 53% King Pharmaceuticals profit fell 53% on continued sales weakness, but results edged analysts' expectations. online.wsj.com |
Amyris Completes IPO With Impressive Partnerships Pipeline: Biotech's Latest Deals The Burrill Report submits: By Marie Daghlian Amyris (AMRS) has completed its much anticipated initial public offering, raising $84.8 million. Though the deal priced at $16 per share, below its expected $18 to $20 range, it posted a 5 percent gain in its first day of trading. Complete Story » seekingalpha.com |
Ryan & Maniskas, LLP Announces Investigation of Clarient, Inc. [Business Wire] - Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Clarient, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Clarient to GE Healthcare, a unit of General Electric Company in a transaction with a value of approximately $580 million. us.rd.yahoo.com |